![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PDPK1 |
Gene summary for PDPK1 |
![]() |
Gene information | Species | Human | Gene symbol | PDPK1 | Gene ID | 5170 |
Gene name | 3-phosphoinositide dependent protein kinase 1 | |
Gene Alias | PDK1 | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | O15530 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5170 | PDPK1 | CCI_1 | Human | Cervix | CC | 6.89e-03 | 5.25e-01 | 0.528 |
5170 | PDPK1 | CCI_2 | Human | Cervix | CC | 9.28e-03 | 6.57e-01 | 0.5249 |
5170 | PDPK1 | LZE4T | Human | Esophagus | ESCC | 1.69e-06 | 1.57e-01 | 0.0811 |
5170 | PDPK1 | LZE7T | Human | Esophagus | ESCC | 8.66e-08 | 3.91e-01 | 0.0667 |
5170 | PDPK1 | LZE8T | Human | Esophagus | ESCC | 5.07e-04 | 1.48e-01 | 0.067 |
5170 | PDPK1 | LZE24T | Human | Esophagus | ESCC | 1.80e-10 | 3.06e-01 | 0.0596 |
5170 | PDPK1 | P1T-E | Human | Esophagus | ESCC | 2.33e-06 | 2.63e-01 | 0.0875 |
5170 | PDPK1 | P2T-E | Human | Esophagus | ESCC | 1.97e-36 | 6.37e-01 | 0.1177 |
5170 | PDPK1 | P4T-E | Human | Esophagus | ESCC | 6.53e-20 | 4.69e-01 | 0.1323 |
5170 | PDPK1 | P5T-E | Human | Esophagus | ESCC | 8.09e-16 | 2.00e-01 | 0.1327 |
5170 | PDPK1 | P8T-E | Human | Esophagus | ESCC | 1.34e-16 | 3.38e-01 | 0.0889 |
5170 | PDPK1 | P9T-E | Human | Esophagus | ESCC | 2.42e-06 | 1.61e-01 | 0.1131 |
5170 | PDPK1 | P10T-E | Human | Esophagus | ESCC | 2.66e-16 | 1.81e-01 | 0.116 |
5170 | PDPK1 | P11T-E | Human | Esophagus | ESCC | 2.75e-06 | 5.00e-01 | 0.1426 |
5170 | PDPK1 | P12T-E | Human | Esophagus | ESCC | 1.43e-21 | 4.33e-01 | 0.1122 |
5170 | PDPK1 | P15T-E | Human | Esophagus | ESCC | 3.99e-16 | 3.01e-01 | 0.1149 |
5170 | PDPK1 | P16T-E | Human | Esophagus | ESCC | 7.32e-15 | 2.52e-01 | 0.1153 |
5170 | PDPK1 | P17T-E | Human | Esophagus | ESCC | 1.88e-05 | 2.14e-01 | 0.1278 |
5170 | PDPK1 | P19T-E | Human | Esophagus | ESCC | 5.11e-06 | 4.33e-01 | 0.1662 |
5170 | PDPK1 | P20T-E | Human | Esophagus | ESCC | 4.73e-14 | 2.67e-01 | 0.1124 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:00070448 | Cervix | CC | cell-substrate junction assembly | 34/2311 | 95/18723 | 3.35e-09 | 3.45e-07 | 34 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
GO:00381278 | Cervix | CC | ERBB signaling pathway | 37/2311 | 121/18723 | 8.57e-08 | 4.88e-06 | 37 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05417113 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
hsa05145110 | Oral cavity | OSCC | Toxoplasmosis | 75/3704 | 112/8465 | 5.28e-07 | 3.16e-06 | 1.61e-06 | 75 |
hsa0406813 | Oral cavity | OSCC | FoxO signaling pathway | 85/3704 | 131/8465 | 7.50e-07 | 4.33e-06 | 2.21e-06 | 85 |
hsa0521515 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0152413 | Oral cavity | OSCC | Platinum drug resistance | 51/3704 | 73/8465 | 5.41e-06 | 2.75e-05 | 1.40e-05 | 51 |
hsa0466012 | Oral cavity | OSCC | T cell receptor signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa04722110 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
hsa0491013 | Oral cavity | OSCC | Insulin signaling pathway | 83/3704 | 137/8465 | 4.83e-05 | 2.00e-04 | 1.02e-04 | 83 |
hsa0521319 | Oral cavity | OSCC | Endometrial cancer | 40/3704 | 58/8465 | 8.86e-05 | 3.19e-04 | 1.62e-04 | 40 |
hsa04919112 | Oral cavity | OSCC | Thyroid hormone signaling pathway | 73/3704 | 121/8465 | 1.63e-04 | 5.52e-04 | 2.81e-04 | 73 |
hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0522315 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415212 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDPK1 | SNV | Missense_Mutation | c.1199N>A | p.Ser400Tyr | p.S400Y | O15530 | protein_coding | deleterious(0.04) | benign(0.044) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PDPK1 | deletion | Frame_Shift_Del | novel | c.1618delC | p.Gln540ArgfsTer65 | p.Q540Rfs*65 | O15530 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
PDPK1 | SNV | Missense_Mutation | c.191N>T | p.Ser64Phe | p.S64F | O15530 | protein_coding | deleterious(0.01) | benign(0.172) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PDPK1 | SNV | Missense_Mutation | c.1542N>A | p.Phe514Leu | p.F514L | O15530 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PDPK1 | SNV | Missense_Mutation | c.191C>T | p.Ser64Phe | p.S64F | O15530 | protein_coding | deleterious(0.01) | benign(0.172) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PDPK1 | SNV | Missense_Mutation | rs753919385 | c.169G>A | p.Glu57Lys | p.E57K | O15530 | protein_coding | tolerated_low_confidence(0.6) | benign(0.028) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
PDPK1 | SNV | Missense_Mutation | novel | c.1565N>T | p.Thr522Met | p.T522M | O15530 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PDPK1 | SNV | Missense_Mutation | rs753410336 | c.1396C>T | p.Arg466Trp | p.R466W | O15530 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AG-3725-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PDPK1 | SNV | Missense_Mutation | c.1514N>A | p.Arg505Gln | p.R505Q | O15530 | protein_coding | tolerated(0.05) | benign(0.177) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
PDPK1 | SNV | Missense_Mutation | c.742T>C | p.Tyr248His | p.Y248H | O15530 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565687 | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | AR-12 | AR-12 | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | SOTRASTAURIN | SOTRASTAURIN | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | RG-1530 | RG-1530 | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | TOZASERTIB | TOZASERTIB | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565590 | CHEMBL1236539 | |
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | CYC-116 | CYC-116 | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565685 | AR-12 | |
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | PF-562271 | PF-00562271 | ||
5170 | PDPK1 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | TAE-684 | TAE-684 |
Page: 1 2 3 |